– Presentation to Include Most Recent Clinical Data from the Five Patient, Low-dose Cohort –
– Company to Host Conference Call on Monday, June 13, 2016 at 2:00 pm CET/ 8:00 am EDT –
AMSTERDAM, the Netherlands, May 19, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that additional data from its Phase I/II trial of AMT-060 in hemophilia B will be presented on June 11, 2016 at the 21st Congress of the European Hematology Association ("EHA") in Copenhagen, Denmark. The oral presentation by the clinical investigator will include new and updated data on five patients enrolled in the study's low-dose cohort.
European Hematolgy Association Data Presentation Details
Abstract #S467: First Results from a Dose-Escalating Study with AAV5 Vector Containing Wild Type Human Factor IX Gene Therapy in Patients with Severe or Moederately-Severe Hemophilia B
Session: Bleeding Disorders
Lead Author: Dr. Frank Leebeek, Professor at the Erasmus University Medical Center in Rotterdam
Date & Time: Saturday, June 11, 2016, 11:30 am CET
Location: Room H4 at the Bella Center in Copenhagen, Denmark
uniQure Conference Call and Webcast
uniQure will host a webcast conference call at 2:00 pm CET/ 8:00 am EDT on Monday, June 13, 2016, to discuss the data from the study. The conference call can be accessed by dialling one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code: 5314178.
|Local - New York, United States of America:||+1 646 254 3367|
|Local - Amsterdam, Netherlands:||+31 (0) 20 716 8256|
|Local - Toronto, Canada:||+1 416 216 4141|
|Local - Brussels, Belgium:||+32 (0) 2 620 0138|
|Local - London, United Kingdom:||+44 (0) 20 3427 1912|
|Local - Paris, France:||+33 (0) 1 76 77 22 29|
|Local - Frankfurt, Germany:||+49 (0) 69 2222 10624|
|Local - Milan, Italy:||+39 02 3600 9869|
Investors may also listen to the webcast of the conference call live through a link provided on both the "Investor" and the "Events" sections of uniQure's website, www.uniQure.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. The webcast replay will be available for at least 72 hours following the call.
About Hemophilia B
Hemophilia B is a serious and rare inherited disease in males characterized by insufficient blood clotting. The condition can lead to repeated and sometimes life-threatening episodes of external and internal bleeding following accidental trauma or medical interventions. The episodes can cause long-term damage, for example to the joints, and can be fatal if they occur in the brain. The deficient blood clotting results from the lack of functional human Factor IX, or hFIX. Treatment of hemophilia B today consists of prophylactic or on-demand protein replacement therapy, in which frequent intravenous administrations of plasma-derived or recombinant hFIX are required to stop or prevent bleeding. Hemophilia B occurs in approximately 1 out of 30,000 live births.
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
uniQure Forward-Looking Statement
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapiesthe success of our collaborations, , and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators' clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2014 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2015 and its 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
CONTACT: uniQure: Eva Mulder Direct : +31 20 240 6103 Main: +31 20 240 6000 e.mulder@uniQure.com Media inquiries: Gretchen Schweitzer or Stephanie May MacDougall Biomedical Communications Direct: +49 172 861 8540 or +49 175 5711562 Main: +49 89 2424 3494 or +1 781 235 3060 firstname.lastname@example.orgSource: uniQure